Combination Therapy With Rituximab and Intravenous or Oral Fludarabine in the First-Line, Systemic Treatment of Patients With Extranodal Marginal Zone B-cell Lymphoma of the Mucosa-Associated Lymphoid Tissue Type.

The article presents a study which examines the role of rituximab and fludarabine in treating extranodal marginal zone lymphomas of the mucosa-associated lymphoid tissue (MALT) type. It notes that patients with de novo extranodal MALT lymphoma received 375 mg/m² rituximab and 25 mg/m² fludarabine for four to six cycles. Results show that 62% of the participants achieved a complete remission (CR) while 38% achieved a partial remission (PR) after the third cycle.